X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (310) 310
Publication (69) 69
Patent (18) 18
Book Chapter (6) 6
Book / eBook (4) 4
Web Resource (3) 3
Conference Proceeding (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (156) 156
index medicus (123) 123
male (109) 109
female (106) 106
middle aged (103) 103
hematology (97) 97
aged (89) 89
adult (87) 87
oncology (86) 86
cancer (76) 76
aged, 80 and over (56) 56
life sciences (54) 54
lymphomas (52) 52
treatment outcome (48) 48
antineoplastic combined chemotherapy protocols - therapeutic use (46) 46
rituximab (46) 46
chemotherapy (45) 45
b-cell lymphoma (41) 41
prognosis (40) 40
lymphoma (35) 35
disease-free survival (33) 33
therapy (29) 29
non-hodgkins-lymphoma (28) 28
retrospective studies (28) 28
[ sdv.can ] life sciences [q-bio]/cancer (27) 27
[sdv.can]life sciences [q-bio]/cancer (25) 25
chemistry (25) 25
survival (25) 25
hemic and lymphatic diseases (24) 24
physics (24) 24
follow-up studies (23) 23
abridged index medicus (22) 22
care and treatment (22) 22
survival rate (22) 22
lymphoma, b-cell, marginal zone - pathology (21) 21
lymphoma, large b-cell, diffuse - drug therapy (21) 21
young adult (21) 21
transplantation (19) 19
adolescent (18) 18
analysis (18) 18
medicine & public health (18) 18
metallurgy (18) 18
recurrence (18) 18
antineoplastic agents - therapeutic use (17) 17
expression (17) 17
survival analysis (17) 17
cyclophosphamide (16) 16
elderly-patients (16) 16
immune system diseases (16) 16
lymphoma, large b-cell, diffuse - mortality (16) 16
neoplasm staging (16) 16
risk factors (16) 16
antineoplastic combined chemotherapy protocols - adverse effects (15) 15
doxorubicin - administration & dosage (15) 15
follicular lymphoma (15) 15
immunology (15) 15
lymphoma, b-cell, marginal zone - therapy (15) 15
microbiology (15) 15
organic chemistry (15) 15
trial (15) 15
antineoplastic combined chemotherapy protocols - administration & dosage (14) 14
beer (14) 14
biochemistry (14) 14
compositions or test papers therefor (14) 14
condition-responsive control in microbiological orenzymological processes (14) 14
drug administration schedule (14) 14
enzymology (14) 14
kaplan-meier estimate (14) 14
lymphoma, large b-cell, diffuse - pathology (14) 14
measuring or testing processes involving enzymes, nucleicacids or microorganisms (14) 14
mutation or genetic engineering (14) 14
processes of preparing such compositions (14) 14
spirits (14) 14
vinegar (14) 14
wine (14) 14
atmospheric and oceanic physics (13) 13
combined modality therapy (13) 13
cyclophosphamide - administration & dosage (13) 13
hygiene (13) 13
lymphoma, b-cell, marginal zone - diagnosis (13) 13
mantle cell lymphoma (13) 13
peptides (13) 13
radiotherapy (13) 13
remission induction (13) 13
time factors (13) 13
disease (12) 12
human necessities (12) 12
lymphoma, mantle-cell - drug therapy (12) 12
medical or veterinary science (12) 12
medical research (12) 12
phase-ii (12) 12
prednisone - administration & dosage (12) 12
prospective studies (12) 12
stem cells (12) 12
antineoplastic agents - administration & dosage (11) 11
diagnosis (11) 11
disease progression (11) 11
hematology, oncology and palliative medicine (11) 11
lymphoma, b-cell, marginal zone - genetics (11) 11
rituximab - administration & dosage (11) 11
more...
Library Location Library Location
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet, The, ISSN 0140-6736, 2016, Volume 388, Issue 10044, pp. 565 - 575
Journal Article
2013, ISBN 9782817803708
Dans les années 1980, le traitement des lymphomes reposait sur la chimiothérapie de type CHOP pour les lymphomes non hodgkiniens (LNH) et de type MOPP pour les... 
Medicine | Toxicology | Hematology | Transplantation of organs, tissues, etc | Oncology | Radiotherapy
Web Resource
Hematology. American Society of Hematology. Education Program, ISSN 1520-4391, 12/2017, Volume 2017, Issue 1, pp. 371 - 378
Splenic marginal zone lymphoma (SMZL) and nodal marginal zone lymphoma (NMZL) are rare indolent chronic B-cell lymphomas. Prognosis is typically good with... 
How Understanding Disease Biology Is Influencing Clinical Decision-Making | Indolent Lymphoma
Journal Article
2015, 2015, ISBN 9783319182568, 553
What should you do when you have restricted resources? Written by the most prominent experts from the North and the South countries, this book offers a unique... 
Clinical & internal medicine | Radiotherapy | Oncology | Medicine & Public Health | Hematology | Tropical Medicine
eBook
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 11/2011, Volume 29, Issue 31, pp. 4079 - 4087
Purpose To evaluate the prognostic value of the cell of origin (COO) in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBLC), prospectively... 
MOLECULAR SUBTYPES | SURVIVAL | ONCOLOGY | RISK STRATIFICATION | R-CHOP | RITUXIMAB | NON-HODGKINS-LYMPHOMAS | CLASSIFICATION | TISSUE MICROARRAY | ELDERLY-PATIENTS | EXPRESSION | Immunohistochemistry | Multivariate Analysis | Predictive Value of Tests | Recurrence | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Prognosis | Prospective Studies | Humans | Middle Aged | Antibodies, Monoclonal, Murine-Derived - administration & dosage | Gene Expression Regulation, Neoplastic | Male | Gene Expression Profiling | Antigens, CD20 - blood | Cisplatin - administration & dosage | Multicenter Studies as Topic | Microarray Analysis | Lymphoma, Large B-Cell, Diffuse - chemistry | Lymphoma, Large B-Cell, Diffuse - immunology | Adult | Female | Neoplasm Proteins - genetics | Dexamethasone - administration & dosage | Lymphoma, Large B-Cell, Diffuse - drug therapy | Lymphoma, Large B-Cell, Diffuse - pathology | Biomarkers, Tumor - analysis | Risk Factors | Proportional Hazards Models | Carboplatin - administration & dosage | Rituximab | Etoposide - administration & dosage | In Situ Hybridization, Fluorescence | Germinal Center - pathology | Cytarabine - administration & dosage | Randomized Controlled Trials as Topic | Disease-Free Survival | Ifosfamide - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Neoplasm, Residual - drug therapy | Neoplasm Proteins - analysis | Aged | Biomarkers, Tumor - genetics | Salvage Therapy - methods | Clinical Medicine | Medical and Health Sciences | Cancer and Oncology | Klinisk medicin | Medicin och hälsovetenskap | Cancer och onkologi
Journal Article
Lancet, The, ISSN 0140-6736, 2011, Volume 378, Issue 9806, pp. 1858 - 1867
Summary Background The outcome of diffuse large B-cell lymphoma has been substantially improved by the addition of the anti-CD20 monoclonal antibody rituximab... 
Internal Medicine | MEDICINE, GENERAL & INTERNAL | MULTICENTER | RESPONSE CRITERIA | AGGRESSIVE LYMPHOMAS | POOR-PROGNOSIS | NON-HODGKINS-LYMPHOMA | REGIMEN | YOUNG-PATIENTS | ELDERLY-PATIENTS | DES-LYMPHOMES | TRANSPLANTATION | Cyclophosphamide - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Prospective Studies | Follow-Up Studies | Humans | Middle Aged | Antibodies, Monoclonal, Murine-Derived - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Cyclophosphamide - adverse effects | Dose-Response Relationship, Drug | Young Adult | Vindesine - adverse effects | Adult | Female | Prednisolone | Doxorubicin - administration & dosage | Severity of Illness Index | Prednisone - administration & dosage | Lymphoma, Large B-Cell, Diffuse - drug therapy | Prednisone - adverse effects | Drug Administration Schedule | Risk Assessment | Rituximab | Treatment Outcome | Bleomycin - administration & dosage | Bleomycin - adverse effects | Vincristine | Lymphoma, Large B-Cell, Diffuse - mortality | Disease-Free Survival | Lymphoma, Large B-Cell, Diffuse - diagnosis | Maximum Tolerated Dose | Adolescent | Survival Analysis | Vindesine - administration & dosage | Doxorubicin - adverse effects | Chemotherapy | Physiological aspects | Lymphomas | B cells | Drug therapy | Methods | Cancer | Dehydrogenases | Toxicity | Population studies | Doxorubicin | Hepatitis | Randomization | Bleomycin | Motivation | Drug dosages | Neutropenia | Cell survival | Hematology | Prednisone | Survival | Patients | Lymphoma | Cyclophosphamide | Lymphocytes B | Monoclonal antibodies | CD20 antigen | Tumors | B-cell lymphoma | Clinical trials | Public speaking | Grants | Clinical medicine | Side effects | lymphoma | survival | International standardization | chemotherapy
Journal Article
Hematology, ISSN 1520-4391, 12/2017, Volume 2017, Issue 1, pp. 371 - 378
Splenic marginal zone lymphoma (SMZL) and nodal marginal zone lymphoma (NMZL) are rare indolent chronic B-cell lymphomas. Prognosis is typically good with... 
MULTICENTER | CLINICAL PRESENTATION | RISK STRATIFICATION | B-CELL LYMPHOMAS | LENALIDOMIDE | PHASE-II | OPEN-LABEL | MUTATIONS | MYD88 L265P | HEMATOLOGY | PROGNOSTIC VALUE | EDUCATION, SCIENTIFIC DISCIPLINES
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2014, Volume 15, Issue 9, pp. 1019 - 1026
Summary Background Present first-line therapy for diffuse large B-cell lymphoma, a subtype of non-Hodgkin lymphoma, is rituximab, cyclophosphamide,... 
Hematology, Oncology and Palliative Medicine | THERAPY | OLDER PATIENTS | ONCOLOGY | FEBRILE NEUTROPENIA | PCI-32765 | CHRONIC LYMPHOCYTIC-LEUKEMIA | CLASSIFICATION | RANDOMIZED CONTROLLED-TRIAL | TARGETING BTK | ELDERLY-PATIENTS | CHEMOTHERAPY | Doxorubicin - therapeutic use | Pyrazoles - therapeutic use | Prognosis | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Cyclophosphamide - adverse effects | Cyclophosphamide - therapeutic use | Dose-Response Relationship, Drug | Young Adult | Non-Randomized Controlled Trials as Topic | Aged, 80 and over | Adult | Female | Lymphoma, Non-Hodgkin - drug therapy | Pyrazoles - adverse effects | Severity of Illness Index | Antigens, CD20 - immunology | Lymphoma, Large B-Cell, Diffuse - drug therapy | Prednisone - adverse effects | Drug Administration Schedule | Administration, Oral | Rituximab | Survival Rate | Treatment Outcome | Lymphoma, Large B-Cell, Diffuse - mortality | Disease-Free Survival | Lymphoma, Large B-Cell, Diffuse - diagnosis | Maximum Tolerated Dose | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Pyrimidines - therapeutic use | Pyrimidines - adverse effects | Vincristine - therapeutic use | Vincristine - adverse effects | Aged | Lymphoma, Non-Hodgkin - mortality | Antigens, CD20 - drug effects | Antibodies, Monoclonal, Murine-Derived - adverse effects | Doxorubicin - adverse effects | Prednisone - therapeutic use | Antibodies, Monoclonal, Murine-Derived - therapeutic use | Lymphoma, Non-Hodgkin - diagnosis | Care and treatment | Anthracyclines | Cyclophosphamide | Prednisone | Corticosteroids | Tumors | Index Medicus
Journal Article
Cancer Research, ISSN 0008-5472, 11/2017, Volume 77, Issue 21, pp. 5721 - 5727
Journal Article
Hematology / the Education Program of the American Society of Hematology. American Society of Hematology. Education Program, ISSN 1520-4391, 2005, Volume 2005, Issue 1, pp. 307 - 313
Journal Article
Bulletin du Cancer, ISSN 0007-4551, 06/2015, Volume 102, Issue 6, pp. S85 - S90
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2013, Volume 14, Issue 6, pp. 525 - 533
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2011, Volume 12, Issue 5, pp. 460 - 468
Summary Background Diffuse large B-cell lymphoma is a common cancer in elderly patients. Although treatment has been standardised in younger patients, no... 
Hematology, Oncology and Palliative Medicine | MAINTENANCE RITUXIMAB | COLONY-STIMULATING FACTOR | PROGNOSTIC-FACTORS | RESPONSE CRITERIA | ONCOLOGY | AGGRESSIVE LYMPHOMAS | MALIGNANT-LYMPHOMAS | NON-HODGKINS-LYMPHOMA | COMPREHENSIVE GERIATRIC ASSESSMENT | DETUDE-DES-LYMPHOMES | CHOP CHEMOTHERAPY | Cyclophosphamide - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Prognosis | Prospective Studies | Humans | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Cyclophosphamide - adverse effects | Aged, 80 and over | Vincristine - administration & dosage | Female | France | Odds Ratio | Doxorubicin - administration & dosage | Prednisone - administration & dosage | Lymphoma, Large B-Cell, Diffuse - drug therapy | Prednisone - adverse effects | Drug Administration Schedule | Lymphoma, Large B-Cell, Diffuse - pathology | Risk Assessment | Risk Factors | Rituximab | Treatment Outcome | Lymphoma, Large B-Cell, Diffuse - mortality | Disease-Free Survival | Analysis of Variance | Belgium | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Survival Analysis | Vincristine - adverse effects | Doxorubicin - adverse effects | Antibodies, Monoclonal, Murine-Derived - therapeutic use | Anthracyclines | Cyclophosphamide | Chemotherapy | Corticosteroids | Oncology, Experimental | Aged patients | Product development | Prednisone | Lymphomas | Research | Cancer | Toxicity | Albumin | Clinical trials | Multivariate analysis | Doxorubicin | Survival | Vincristine | Side effects | Motivation | Age | rituximab | B-cell lymphoma | Geriatrics | Neutropenia
Journal Article
Intensive care medicine, ISSN 0342-4642, 08/2019, pp. 1 - 2
Journal Article